Relapsed Or Refractory B Cell Non Hodgkin Lymphoma clinical trials

Explore recruiting relapsed or refractory b cell non hodgkin lymphoma clinical trials.

Recruiting relapsed or refractory b cell non hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory B Cell Non Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

France, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Italy, Spain, Czechia, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Italy, Spain, Belgium, Poland, Denmark

Human Pharmacology (Phase I)- Other EU CTIS Study details

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) )

Germany, Spain, Denmark, Italy, Sweden, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Or Refractory B Cell Non Hodgkin Lymphoma trials by city

Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Toronto Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Vancouver Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Montreal Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Calgary Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Edmonton Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Ottawa Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Winnipeg Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Quebec City Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Hamilton Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Kitchener Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in London Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Halifax Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in New York Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Los Angeles Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Chicago Relapsed Or Refractory B Cell Non Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease